Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Follow-Up Questions
¿Quién es el CEO de Sequana Medical NV?
Ian Crosbie es el Chief Executive Officer de Sequana Medical NV, se unió a la empresa desde 2019.
¿Qué tal es el rendimiento del precio de la acción SQNMF?
El precio actual de SQNMF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Sequana Medical NV?
Sequana Medical NV pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Sequana Medical NV?
La capitalización bursátil actual de Sequana Medical NV es $NaN
¿Es Sequana Medical NV una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Sequana Medical NV, incluyendo 4 fuerte compra, 4 compra, 2 mantener, 0 venta, y 4 fuerte venta
